Neuron Specific Enolase (NSE), CSF
Enolase is an enzyme involved in glycolysis and is expressed in many tissues. It is most highly expressed in neurons and neural tissue, where it can account for as much as 3% of total protein. Because Neuron-Specific-Enolase (NSE) is the main enolase found in neural tissues, its detection can be used as a marker for neuroendocrine injury and/or proliferation. Concentrations of NSE in serum or CSF can be elevated in multiple conditions that cause destruction to neural tissues. Progressive dementias (such as Creutzfeldt-Jacob Disease), brain ischemia, and head trauma can all cause elevated NSE in the CSF or serum.
In the oncology setting, immunohistochemical stains for NSE may be used in anatomic pathology specimens to help diagnose neuroblastoma and other neuroendocrine tumors, although other more specific markers are more commonly used. Serum or CSF measurements of NSE can be used to help diagnose and follow patients with small-cell lung carcinoma (SCLC). The majority of these patients will have elevated serum NSE concentrations at diagnosis. Similarly, over half of patients with carcinoid tumors also have elevated serum NSE. Pancreatic islet cell tumors and neuroblastomas can also express NSE. Concentrations of NSE reflect the growth of the tumor or the extent of neuronal tissue pathology. Because of this, NSE levels can be tracked over time to monitor the rise or fall of levels subsequent to treatment or remission.
NSE has also been studied in the context of coma. Elevated levels of serum NSE have been shown to help predict the occurrence of a persistent coma. Higher plasma NSE concentrations have also been associated with mortality and delirium in septic patients. All of these indications support the general finding that NSE release follows neuronal injury, regardless of the mechanism of that injury. When trending results over time it is essential that the same laboratory method be used. The biological half-life of NSE in body fluids is approximately 24 hours.
- As an aid in diagnosis of neuroblastoma
- Treatment monitoring and prognosis of neuroblastoma
- Treatment monitoring and prognosis Neuron-Specific-Enolase secreting tumors
- As an aid in diagnosis and management of neural injury
When used as a tumor marker, serum NSE concentrations should be interpreted in light of past levels, assuming the tumor type has been determined to be one which secretes NSE.
Serum concentrations should decrease quickly given the short half-life of NSE in serum. If NSE levels remain elevated, tumor resistance or persistence is suggested. When used to help differentiate a lung mass, elevated NSE can suggest a paraneoplastic syndrome or an occult small cell lung carcinoma. In other contexts, NSE is merely supportive of neural tissue damage or neuroendocrine neoplasm.
Increased in:
- Any condition injurious to neural tissue
- Neoplasms which secrete NSE
Reference ranges vary based on methodology.
- Serum: 0-30 ng/ml or <15 ng/ml
- CSF: 1.0-7.0 ng/ml
Chemiluminescent immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).
Cerebrospinal fluid collected in a sterile container or tube.
Stability
- Ambient: 12-24 hours
- Refrigerated: 3-5 days
- Frozen: 30 days
1-5 days
- Crit Care Med. 1997 Jul;25(7):1133-8. [PMID: 9233737]
- J Crit Care. 2016 Dec;36:18-23. [PMID: 27546742]
- J Cancer Res Ther. 2016 Oct;12(Supplement):34-36. [PMID: 27721249]
- Laboratory Test Handbook Concise: With Disease Index, 3rd Edition by David S. Jacobs, Wayne R. Demott, Dwight K. Oxley. Lexi-Comp, Hudson, OH. 2004. ISBN-13: 978-1591950806